RudaCure Inc., a company specializing in novel drug development, was selected for the Grand Prize at 'Core Innovation Korea 2024' hosted by Kookmin Ilbo and Cookie News.
Unlike existing treatments, RudaCure developed a dry eye disease treatment RCI001 that shortens drug exposure duration through excellent tear production, corneal damage recovery, anti-inflammatory, and antioxidant effects.
RCI001 demonstrates therapeutic effects within 24 weeks, and is recognized for overcoming the slow onset and side effects (hyperemia, hemorrhage, elevated intraocular pressure, burning upon instillation) of existing treatments. It also addresses the limitations of steroid-based treatments, enabling long-term use and resolving existing market discomfort.
RudaCure plans to complete domestic Phase 1 clinical trials by 2024, and conduct domestic and US Phase 2 clinical trials in 2025-2026. It also plans to actively pursue global technology transfer through overseas clinical data.
